Patient Groups Push Back Against Gilead's Pricey HIV Prevention Treatment

By Reuters
NYT Business Day
Gilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.
Published date: August 7, 2019 at 07:39PM
Reuters
New York Times article